Overview

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
Completed

Trial end date:
2020-12-09

Target enrollment:

Participant gender:

Summary

This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies, Monoclonal
Upadacitinib